The initiation of the Pfizer-BioNtech COVID-19 vaccine in the United Kingdom and the United States of
America resulted in anaphylactic allergic reactions in 5 vaccines. The American College of Allergy,
Asthma and Immunology (ACAAI), the Centre for Disease Control and Prevention (CDC), the UK
Medicines and Healthcare products Regulatory Agency (MHRA) in collaboration with the British Society
of Allergy and Clinical Immunology (BSACI), the Hellenic Society of Allergy and Clinical Immunology
(BSACI) and the Hellenic National Committee for Vaccination have produced guidance on the risk of
allergic reaction during vaccination.
Read More
Announcement of the European Association of Allergy & Clinical Immunology (EAACI) in collaboration with the ARIA (Allergic Rhinitis and its Impact on Asthma) group on severe allergic reactions to COVID-19 vaccines
On 9 December 2020, the UK Medicines and Healthcare products Regulatory Agency (MHRA) announced
two anaphylactic reactions and one possible allergic reaction after the administration of the BNT162b2
vaccine for the COVID-19 pandemic. Until the exact causes of these reactions are investigated, the
MHRA has issued the following interim guidance to the UK National Health Service (NHS) as a
precautionary measure: "Any person with a history of anaphylaxis to a vaccine, medicine or food should
not have the Pfizer/BioNTech vaccine. The second dose should not be given to anyone who has had an
anaphylactic reaction after receiving the first dose." "Patients should discuss any questions and history
of severe allergies with their doctor before getting vaccinated."
Read More
Νοσοκομείο Παίδων Αθηνών «Παναγιώτη και Αγλαΐας Κυριακού»
Ιατρική Σχολή Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών
